Evidence map›Paper›PMID 39205958›Full record

ArticleCardiology research2024

Efficacy of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis.

Jordan Llerena-Velastegui, Melisa Santamaria-Lasso, Melany Mejia-Mora, Mauricio Santander-Aldean, Andrea Granda-Munoz, Claudia Hurtado-Alzate, Ana Clara Fonseca Souza de Jesus, Jurgen Baldelomar-Ortiz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jordan Llerena-VelasteguiMedical School, Pontifical Catholic University of Ecuador, Quito, Ecuador.ORCID https://orcid.org/0009-0002-4246-0980
Melisa Santamaria-LassoMedical School, Pontifical Catholic University of Ecuador, Quito, Ecuador.ORCID https://orcid.org/0009-0002-5523-6638
Melany Mejia-MoraMedical School, Pontifical Catholic University of Ecuador, Quito, Ecuador.ORCID https://orcid.org/0000-0001-7875-5428
Mauricio Santander-AldeanMedical School, Pontifical Catholic University of Ecuador, Quito, Ecuador.ORCID https://orcid.org/0000-0002-0131-6651
Andrea Granda-MunozMedical School, Pontifical Catholic University of Ecuador, Quito, Ecuador.ORCID https://orcid.org/0009-0006-1684-8403
Claudia Hurtado-AlzateMedical School, University of La Sabana, Cundinamarca, Colombia.ORCID https://orcid.org/0000-0001-8291-5180
Ana Clara Fonseca Souza de JesusMedical School, Faculdade de Minas - FAMINAS-BH, Belo Horizonte, Brazil.ORCID https://orcid.org/0000-0001-8505-8444
Jurgen Baldelomar-OrtizMedical School, Private University of the Valley, La Paz, Bolivia.ORCID https://orcid.org/0009-0000-3213-5282

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Non-ischemic dilated cardiomyopathy (NIDCM) is a form of heart failure with a poor prognosis and unclear optimal management. The aim of the study was to systematically review the literature and assess the efficacy and safety of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors in the management of chronic heart failure secondary to NIDCM and explore their putative mechanisms of action. Methods: Studies from 1990 to 2023 were reviewed using PubMed and EMBASE, focusing on their effects on left ventricular ejection fraction (LVEF) in NIDCM patients, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: Beta-blockers showed a significant beneficial effect on LVEF improvement in NIDCM, with an overall effect size of Cohen's Conclusions: The study highlights the efficacy of carvedilol in improving LVEF in NIDCM patients over ACE inhibitors, recommends beta-blockers as first-line therapy, and advocates further research on ACE inhibitors.

Indexed as

ACE inhibitorsBeta-blockersLeft ventricular ejection fractionMeta-analysisNon-ischemic dilated cardiomyopathySystematic review

Identifiers

PMID39205958
PMCPMC11349132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.